2 ms·
Vioxx gets complicated; other NSAIDs, including non-selective ones, turn out to have a pretty nasty cardiac risk profile too, and the withdrawal harmed a lot of
by ceejayoz 5y ago
Vioxx gets complicated; other NSAIDs, including non-selective ones, turn out to have a pretty nasty cardiac risk profile too, and the withdrawal harmed a lot of patients who relied on it.
https://pharmaceutical-journal.com/article/feature/still-feeling-the-vioxx-pain https://pharmaceutical-journal.com/article/feature/still-fee...
> After Vioxx was withdrawn, there were numerous papers and discussion on the increased risk of cardiovascular events with all NSAIDS and labelling changes were made. However, Silman argues that it has still not been proven in observational studies that Vioxx’s cardiovascular events were any higher than, for instance, diclofenac, a popular non-selective NSAID.
> It proved to be complex: not all COX-2 inhibitors have the same cardiovascular risks and not all non-selective NSAIDs have the same cardiovascular risks. “If the VIGOR study had been comparing Vioxx against diclofenac, it is entirely plausible that it would have shown no difference in cardiovascular events,” Silman points out.
> ...
> If MSD had not withdrawn the drug, perhaps regulators would have deemed that it not be used in patients with pre-existing heart conditions and the elderly, Silman ponders. “It was not necessarily a given that Vioxx should have been withdrawn completely. For instance, diclofenac has not been withdrawn and is still on the market but with advice to use with caution,” he says.
> Neither does Silman think Vioxx should have been withdrawn, since it proved to be a very effective anti-inflammatory drug. “The joke at the time of its withdrawal was that every rheumatologist was stockpiling Vioxx because of its efficacy.” The Vioxx story is not so simple and it was not about “Vioxx being the bad guy”, he says.